Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Sell
36
ACHV Quote, Financials, Valuation and Earnings
Last price:
$4.80
Seasonality move
:
13.64%
Day range:
$4.70 - $5.19
52-week range:
$1.84 - $5.78
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
7.57x
Volume:
1.5M
Avg. volume:
829K
1-year change:
5.52%
Market cap:
$254.5M
Revenue:
--
EPS (TTM):
-$1.38
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ACHV
Achieve Life Sciences, Inc.
|
-- | -$0.26 | -- | -22.63% | $15.89 |
|
AUPH
Aurinia Pharmaceuticals, Inc.
|
$67.7M | $0.16 | 25.05% | 2133.71% | $16.67 |
|
EDSA
Edesa Biotech, Inc.
|
-- | -- | -- | -- | $10.33 |
|
LEXX
Lexaria Bioscience Corp.
|
$50K | -- | 63.1% | -- | $6.00 |
|
ONCY
Oncolytics Biotech, Inc.
|
-- | -$0.05 | -- | -15.25% | $5.49 |
|
STME
StimCell Energetics, Inc.
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ACHV
Achieve Life Sciences, Inc.
|
$4.78 | $15.89 | $254.5M | -- | $0.00 | 0% | -- |
|
AUPH
Aurinia Pharmaceuticals, Inc.
|
$15.31 | $16.67 | $2B | 27.29x | $0.00 | 0% | 8.13x |
|
EDSA
Edesa Biotech, Inc.
|
$1.69 | $10.33 | $11.9M | -- | $0.00 | 0% | 31.22x |
|
LEXX
Lexaria Bioscience Corp.
|
$1.12 | $6.00 | $24.9M | -- | $0.00 | 0% | 28.57x |
|
ONCY
Oncolytics Biotech, Inc.
|
$0.98 | $5.49 | $104.1M | -- | $0.00 | 0% | -- |
|
STME
StimCell Energetics, Inc.
|
$0.3201 | -- | $6.6M | -- | $0.00 | 0% | 1,937.12x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ACHV
Achieve Life Sciences, Inc.
|
22.85% | 2.734 | 5.99% | 4.94x |
|
AUPH
Aurinia Pharmaceuticals, Inc.
|
17.62% | -0.123 | 5.37% | 5.02x |
|
EDSA
Edesa Biotech, Inc.
|
-- | -0.273 | -- | 18.80x |
|
LEXX
Lexaria Bioscience Corp.
|
2.06% | -1.067 | 0.6% | 3.11x |
|
ONCY
Oncolytics Biotech, Inc.
|
87.89% | 4.153 | 0.41% | 1.61x |
|
STME
StimCell Energetics, Inc.
|
-54.35% | 4.095 | 8.86% | 0.00x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ACHV
Achieve Life Sciences, Inc.
|
-$54K | -$14.7M | -139.57% | -189.88% | -- | -$11.3M |
|
AUPH
Aurinia Pharmaceuticals, Inc.
|
$65.3M | $30.7M | 17.52% | 21.42% | 41.75% | $44.9M |
|
EDSA
Edesa Biotech, Inc.
|
-$25.8K | -$1.9M | -80.33% | -80.46% | -- | -$1.8M |
|
LEXX
Lexaria Bioscience Corp.
|
$152.6K | -$2.5M | -144.76% | -147.19% | -2155.4% | -$3.6M |
|
ONCY
Oncolytics Biotech, Inc.
|
-$67.5K | -$10M | -540.79% | -635.07% | -- | -$4.9M |
|
STME
StimCell Energetics, Inc.
|
-- | -$254.1K | -- | -- | -- | -$108.1K |
Achieve Life Sciences, Inc. vs. Competitors
-
Which has Higher Returns ACHV or AUPH?
Aurinia Pharmaceuticals, Inc. has a net margin of -- compared to Achieve Life Sciences, Inc.'s net margin of 42.95%. Achieve Life Sciences, Inc.'s return on equity of -189.88% beat Aurinia Pharmaceuticals, Inc.'s return on equity of 21.42%.
Company Gross Margin Earnings Per Share Invested Capital ACHVAchieve Life Sciences, Inc.-- -$0.28 $43.6M AUPHAurinia Pharmaceuticals, Inc.88.87% $0.23 $444M -
What do Analysts Say About ACHV or AUPH?
Achieve Life Sciences, Inc. has a consensus price target of $15.89, signalling upside risk potential of 232.4%. On the other hand Aurinia Pharmaceuticals, Inc. has an analysts' consensus of $16.67 which suggests that it could grow by 8.86%. Given that Achieve Life Sciences, Inc. has higher upside potential than Aurinia Pharmaceuticals, Inc., analysts believe Achieve Life Sciences, Inc. is more attractive than Aurinia Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ACHVAchieve Life Sciences, Inc.6 0 0 AUPHAurinia Pharmaceuticals, Inc.4 3 0 -
Is ACHV or AUPH More Risky?
Achieve Life Sciences, Inc. has a beta of 1.690, which suggesting that the stock is 68.981% more volatile than S&P 500. In comparison Aurinia Pharmaceuticals, Inc. has a beta of 1.425, suggesting its more volatile than the S&P 500 by 42.546%.
-
Which is a Better Dividend Stock ACHV or AUPH?
Achieve Life Sciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Aurinia Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Achieve Life Sciences, Inc. pays -- of its earnings as a dividend. Aurinia Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ACHV or AUPH?
Achieve Life Sciences, Inc. quarterly revenues are --, which are smaller than Aurinia Pharmaceuticals, Inc. quarterly revenues of $73.5M. Achieve Life Sciences, Inc.'s net income of -$14.4M is lower than Aurinia Pharmaceuticals, Inc.'s net income of $31.6M. Notably, Achieve Life Sciences, Inc.'s price-to-earnings ratio is -- while Aurinia Pharmaceuticals, Inc.'s PE ratio is 27.29x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Achieve Life Sciences, Inc. is -- versus 8.13x for Aurinia Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ACHVAchieve Life Sciences, Inc.-- -- -- -$14.4M AUPHAurinia Pharmaceuticals, Inc.8.13x 27.29x $73.5M $31.6M
-
Which has Higher Returns ACHV or EDSA?
Edesa Biotech, Inc. has a net margin of -- compared to Achieve Life Sciences, Inc.'s net margin of --. Achieve Life Sciences, Inc.'s return on equity of -189.88% beat Edesa Biotech, Inc.'s return on equity of -80.46%.
Company Gross Margin Earnings Per Share Invested Capital ACHVAchieve Life Sciences, Inc.-- -$0.28 $43.6M EDSAEdesa Biotech, Inc.-- -$0.25 $14.1M -
What do Analysts Say About ACHV or EDSA?
Achieve Life Sciences, Inc. has a consensus price target of $15.89, signalling upside risk potential of 232.4%. On the other hand Edesa Biotech, Inc. has an analysts' consensus of $10.33 which suggests that it could grow by 550.89%. Given that Edesa Biotech, Inc. has higher upside potential than Achieve Life Sciences, Inc., analysts believe Edesa Biotech, Inc. is more attractive than Achieve Life Sciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ACHVAchieve Life Sciences, Inc.6 0 0 EDSAEdesa Biotech, Inc.1 0 0 -
Is ACHV or EDSA More Risky?
Achieve Life Sciences, Inc. has a beta of 1.690, which suggesting that the stock is 68.981% more volatile than S&P 500. In comparison Edesa Biotech, Inc. has a beta of 0.078, suggesting its less volatile than the S&P 500 by 92.204%.
-
Which is a Better Dividend Stock ACHV or EDSA?
Achieve Life Sciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Edesa Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Achieve Life Sciences, Inc. pays -- of its earnings as a dividend. Edesa Biotech, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ACHV or EDSA?
Achieve Life Sciences, Inc. quarterly revenues are --, which are smaller than Edesa Biotech, Inc. quarterly revenues of --. Achieve Life Sciences, Inc.'s net income of -$14.4M is lower than Edesa Biotech, Inc.'s net income of -$1.7M. Notably, Achieve Life Sciences, Inc.'s price-to-earnings ratio is -- while Edesa Biotech, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Achieve Life Sciences, Inc. is -- versus 31.22x for Edesa Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ACHVAchieve Life Sciences, Inc.-- -- -- -$14.4M EDSAEdesa Biotech, Inc.31.22x -- -- -$1.7M
-
Which has Higher Returns ACHV or LEXX?
Lexaria Bioscience Corp. has a net margin of -- compared to Achieve Life Sciences, Inc.'s net margin of -2178.51%. Achieve Life Sciences, Inc.'s return on equity of -189.88% beat Lexaria Bioscience Corp.'s return on equity of -147.19%.
Company Gross Margin Earnings Per Share Invested Capital ACHVAchieve Life Sciences, Inc.-- -$0.28 $43.6M LEXXLexaria Bioscience Corp.91.15% -$0.14 $5.3M -
What do Analysts Say About ACHV or LEXX?
Achieve Life Sciences, Inc. has a consensus price target of $15.89, signalling upside risk potential of 232.4%. On the other hand Lexaria Bioscience Corp. has an analysts' consensus of $6.00 which suggests that it could grow by 376.19%. Given that Lexaria Bioscience Corp. has higher upside potential than Achieve Life Sciences, Inc., analysts believe Lexaria Bioscience Corp. is more attractive than Achieve Life Sciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ACHVAchieve Life Sciences, Inc.6 0 0 LEXXLexaria Bioscience Corp.0 0 0 -
Is ACHV or LEXX More Risky?
Achieve Life Sciences, Inc. has a beta of 1.690, which suggesting that the stock is 68.981% more volatile than S&P 500. In comparison Lexaria Bioscience Corp. has a beta of 0.628, suggesting its less volatile than the S&P 500 by 37.221%.
-
Which is a Better Dividend Stock ACHV or LEXX?
Achieve Life Sciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lexaria Bioscience Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Achieve Life Sciences, Inc. pays -- of its earnings as a dividend. Lexaria Bioscience Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ACHV or LEXX?
Achieve Life Sciences, Inc. quarterly revenues are --, which are smaller than Lexaria Bioscience Corp. quarterly revenues of $174K. Achieve Life Sciences, Inc.'s net income of -$14.4M is lower than Lexaria Bioscience Corp.'s net income of -$2.7M. Notably, Achieve Life Sciences, Inc.'s price-to-earnings ratio is -- while Lexaria Bioscience Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Achieve Life Sciences, Inc. is -- versus 28.57x for Lexaria Bioscience Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ACHVAchieve Life Sciences, Inc.-- -- -- -$14.4M LEXXLexaria Bioscience Corp.28.57x -- $174K -$2.7M
-
Which has Higher Returns ACHV or ONCY?
Oncolytics Biotech, Inc. has a net margin of -- compared to Achieve Life Sciences, Inc.'s net margin of --. Achieve Life Sciences, Inc.'s return on equity of -189.88% beat Oncolytics Biotech, Inc.'s return on equity of -635.07%.
Company Gross Margin Earnings Per Share Invested Capital ACHVAchieve Life Sciences, Inc.-- -$0.28 $43.6M ONCYOncolytics Biotech, Inc.-- -$0.10 $682.8K -
What do Analysts Say About ACHV or ONCY?
Achieve Life Sciences, Inc. has a consensus price target of $15.89, signalling upside risk potential of 232.4%. On the other hand Oncolytics Biotech, Inc. has an analysts' consensus of $5.49 which suggests that it could grow by 459.36%. Given that Oncolytics Biotech, Inc. has higher upside potential than Achieve Life Sciences, Inc., analysts believe Oncolytics Biotech, Inc. is more attractive than Achieve Life Sciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ACHVAchieve Life Sciences, Inc.6 0 0 ONCYOncolytics Biotech, Inc.3 1 0 -
Is ACHV or ONCY More Risky?
Achieve Life Sciences, Inc. has a beta of 1.690, which suggesting that the stock is 68.981% more volatile than S&P 500. In comparison Oncolytics Biotech, Inc. has a beta of 0.880, suggesting its less volatile than the S&P 500 by 11.965%.
-
Which is a Better Dividend Stock ACHV or ONCY?
Achieve Life Sciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oncolytics Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Achieve Life Sciences, Inc. pays -- of its earnings as a dividend. Oncolytics Biotech, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ACHV or ONCY?
Achieve Life Sciences, Inc. quarterly revenues are --, which are smaller than Oncolytics Biotech, Inc. quarterly revenues of --. Achieve Life Sciences, Inc.'s net income of -$14.4M is lower than Oncolytics Biotech, Inc.'s net income of -$10.5M. Notably, Achieve Life Sciences, Inc.'s price-to-earnings ratio is -- while Oncolytics Biotech, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Achieve Life Sciences, Inc. is -- versus -- for Oncolytics Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ACHVAchieve Life Sciences, Inc.-- -- -- -$14.4M ONCYOncolytics Biotech, Inc.-- -- -- -$10.5M
-
Which has Higher Returns ACHV or STME?
StimCell Energetics, Inc. has a net margin of -- compared to Achieve Life Sciences, Inc.'s net margin of --. Achieve Life Sciences, Inc.'s return on equity of -189.88% beat StimCell Energetics, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ACHVAchieve Life Sciences, Inc.-- -$0.28 $43.6M STMEStimCell Energetics, Inc.-- -$0.01 -$903.1K -
What do Analysts Say About ACHV or STME?
Achieve Life Sciences, Inc. has a consensus price target of $15.89, signalling upside risk potential of 232.4%. On the other hand StimCell Energetics, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Achieve Life Sciences, Inc. has higher upside potential than StimCell Energetics, Inc., analysts believe Achieve Life Sciences, Inc. is more attractive than StimCell Energetics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ACHVAchieve Life Sciences, Inc.6 0 0 STMEStimCell Energetics, Inc.0 0 0 -
Is ACHV or STME More Risky?
Achieve Life Sciences, Inc. has a beta of 1.690, which suggesting that the stock is 68.981% more volatile than S&P 500. In comparison StimCell Energetics, Inc. has a beta of 48.081, suggesting its more volatile than the S&P 500 by 4708.057%.
-
Which is a Better Dividend Stock ACHV or STME?
Achieve Life Sciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. StimCell Energetics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Achieve Life Sciences, Inc. pays -- of its earnings as a dividend. StimCell Energetics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ACHV or STME?
Achieve Life Sciences, Inc. quarterly revenues are --, which are smaller than StimCell Energetics, Inc. quarterly revenues of --. Achieve Life Sciences, Inc.'s net income of -$14.4M is lower than StimCell Energetics, Inc.'s net income of -$265.6K. Notably, Achieve Life Sciences, Inc.'s price-to-earnings ratio is -- while StimCell Energetics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Achieve Life Sciences, Inc. is -- versus 1,937.12x for StimCell Energetics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ACHVAchieve Life Sciences, Inc.-- -- -- -$14.4M STMEStimCell Energetics, Inc.1,937.12x -- -- -$265.6K
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 62x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 38x
Buy
63
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 40x
Alerts
Buy
54
SMX alert for Dec 5
SMX (Security Matters) Plc [SMX] is up 154.74% over the past day.
Sell
15
HOV alert for Dec 5
Hovnanian Enterprises, Inc. [HOV] is down 22.58% over the past day.
Buy
67
NUTX alert for Dec 5
Nutex Health, Inc. [NUTX] is up 18.9% over the past day.
